Industry coverage tracks the money around peptides: Eli Lilly and Novo Nordisk earnings, pipeline shifts, M&A, IPOs, peptide CDMO capacity, and the telehealth and pharmacy economy that GLP-1s built.
The two stories that keep moving the most market cap: how fast oral GLP-1s reach approval (orforglipron, oral semaglutide, oral wegovy, danuglipron's exit), and what happens to the compounded-peptide channel as the FDA tightens. Hims, Ro, LifeMD, GoodRx, and Amazon Pharmacy have all rerouted distribution in the past year. Behind them, contract manufacturers like Bachem, PolyPeptide, and BASF have been the bottleneck no one talked about until they were.
Stories here name the company, the deal, and the dollars. Earnings, partnership, regulatory hit — whatever moved the share price gets covered.
Italian producer Italgel launched avvera, a 'next-generation collagen for skin beauty,' on June 12, 2026 backed by a published double-blind parallel-group eight-week study conducted by Bionos Biotech S.L. in Spain. The randomized trial enrolled 67 healthy women aged 38-66 who received 2.5 g/day of either avvera or an established comparator collagen. Avvera showed greater reductions in crow's-feet wrinkle area and length at day 28, though between-group differences narrowed by day 56. Skin hydration improved 43.5% versus 42.9% for the active control at day 56. Italgel attributes the faster onset to its trademarked 'High-Dration System' production technology, which increases water storage in the skin while reducing transepidermal water loss via improved epidermal barrier function. The launch enters the cosmetic-peptide market alongside GELITA's CURADERM at Vitafoods Europe.
Collagen specialist GELITA debuted as the official collagen sponsor at Vitafoods Europe 2026, launching its new Bioactive Collagen Peptide CURADERM for skin barrier integrity and oral/gum health applications. CURADERM joins GELITA's collagen-peptide product family alongside VERISOL (skin elasticity and anti-wrinkle), BODYBALANCE (muscle and body composition), TENDOFORTE (tendon and ligament), and FORTIGEL (joint cartilage). The launch underscores the cosmetic and functional peptide market's continued bifurcation between branded bioactive collagen peptides (with claim-supporting clinical data) and commodity collagen powders. BASF earlier launched NeoHelix Regenerate and SkinNexus Collag3n at in-cosmetics Global Paris in April, completing a strong 2026 cycle of cosmetic-peptide industry launches just as the wellness market navigates the FDA July PCAC peptide-reclassification decision.
Lexaria Bioscience (NASDAQ: LEXX) announced June 9, 2026 that dosing has been completed in Animal Study #2 (GLP-1-A26-2) evaluating its DehydraTECH oral peptide delivery platform with two next-generation GLP-1 drugs: Eli Lilly's retatrutide (triple GIP/GLP-1/glucagon agonist) and Novo Nordisk's amycretin (unimolecular GLP-1/amylin agonist). The study tested formulation enhancements designed to improve DehydraTECH performance and stake intellectual property claims on next-generation oral GLP-1 delivery. The data follows Lexaria's April 23 study launch and feeds the broader oral GLP-1 platform competition with Novo Nordisk's Wegovy pill (3M US prescriptions in 5 months) and Lilly's orforglipron (Foundayo, approved April 2026). Lexaria's industry update June 17 framed the oral GLP-1 pill segment as 'billions in new industry sales' potential.
Peptide World Congress 2026 opens today (June 19-20, 2026) at Arizona Biltmore, LXR Hotels & Resorts in Phoenix, bringing together the clinical-peptide-prescriber community for two days of practitioner-focused sessions on therapeutic peptide protocols, dosing, indications, and case-based clinical reasoning. The agenda spans cellular aging, regenerative protocols, and clinical applications across orthopedic, metabolic, immune, and longevity indications. The conference falls roughly five weeks ahead of the July 23-24 FDA Pharmacy Compounding Advisory Committee meeting, which will determine whether BPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin, and the other Category-2-reclassified peptides advance toward 503A compounding-list eligibility. The community-conference format reflects how rapidly clinical peptide prescribing has moved from off-label specialty practice to a formal CME-adjacent ecosystem.
AmbioPharm announced June 16 a $118.96 million expansion of its Aiken County, South Carolina headquarters, adding a 68,000-square-foot modular manufacturing building at its existing 1024 Dittman Court campus in North Augusta and creating more than 200 new jobs. The facility will offer commercial-scale GMP synthesis including solid-phase peptide synthesis (SPPS), liquid-phase peptide synthesis (LPPS), and hybrid approaches, mirroring upgrades made to AmbioPharm's Shanghai facility. Operations target end of 2027. The announcement arrives roughly three weeks after the May 27, 2026 close of CordenPharma's acquisition of AmbioPharm, which secured CordenPharma a second US peptide site (joining Boulder, Colorado) and its first Shanghai-based supply node. AmbioPharm shareholders are reinvesting in the combined entity. The expansion is the largest single US peptide-manufacturing capacity addition of 2026 to date.
Barclays raised its price target on Hims & Hers Health (NYSE: HIMS) to $39 from $29 on June 17, citing improved customer-momentum signals from alternative data since the March 9 Novo Nordisk collaboration announcement and the upcoming peptide-catalyst opportunity tied to the July 23-24 PCAC meeting. The firm maintained an Overweight rating; the $39 target implies roughly 21% upside from the prior close. HIMS gained about 6% on the day. Leerink reiterated Market Perform with a $25 PT ahead of the same PCAC meeting, framing potential PCAC approval as an upside catalyst for Hims' growth outlook beyond 2027. Hims acquired a California peptide manufacturing facility in 2025 and added in-house lab testing capacity ahead of the regulatory window.
South Korea's D&D Pharmatech and LG AI Research announced June 17 a joint development agreement for AI-designed next-generation oral peptide drugs. LG AI Research will use its EXAONE Discovery pharmaceutical AI platform, which analyzes disease-causing protein structures to design optimal peptide sequences, while D&D contributes its oral peptide delivery experience and obesity-pipeline programs. D&D's shares closed up 16.59% on the announcement. The deal extends D&D's late-cycle pipeline momentum, following the April 2026 $1.3M Pfizer research contract on oral obesity peptides after Pfizer's Metsera acquisition, and the June ADA showcase of Korean monthly-GLP-1 programs.
Bloomberg Businessweek published a long-form feature June 17 mapping the peptide gold rush as black-market wellness drugs move toward legitimacy ahead of the July 23-24 PCAC meeting. The piece centers on Janoshik Analytical, a Prague-based purity-testing operation that grew its peptide test volume by more than 1,200% from 2023 to 2025 and reports almost nine figures in annual revenue. Investor estimates put the current US black market at $1-3 billion. Bloomberg reports peptides are now being pitched to menopausal suburban moms and offered at med spas as a casual add-on to Botox, with FDA-regulated peptide pricing strategy now an active question for entrepreneurs, investors, and incumbents alike.
Azitra, Inc. (NYSE American: AZTR), a clinical-stage precision-dermatology biotech, announced June 16 a strategic launch into the cosmetic and cosmeceutical markets with a new protein and peptide program built on proprietary filaggrin technologies and the company's microbial genetic-engineering platform. Cofounder and COO Travis Whitfill, Ph.D., MPH will present pipeline updates at the BIO International Convention in San Diego on June 23, 2026 at 4:45 PM PT. The stock gained 87% the same day on roughly 251x average trading volume, closing at $0.35. Filaggrin is a structural protein critical for skin-barrier function and a target of growing interest in barrier-repair cosmeceuticals.
MultiValent Biotherapies announced June 16 a first closing of $27.425 million in Series A financing to advance MVB-101, a PSMA × folate-receptor-alpha (FRα) dual-target peptide-drug conjugate licensed from China-based Coherent Biopharma (originally CBP-1018). MVB-101 binds two validated prostate-cancer targets simultaneously; existing PDCs and radioligand therapies (Pluvicto, Lutathera) hit one target each. MultiValent holds exclusive global rights outside greater China. A Phase 1b/2a clinical trial in a subgroup of prostate cancer patients is planned to start in Q3 2026. The launch adds another oncology PDC to a field still dominated by Pluvicto (lutetium-177 PSMA-617), Lutathera, and Pfizer's AVA6000 FAP-Dox.
The Business Group on Health's June 2026 survey of 105 large US employers found 67% currently cover GLP-1 drugs for weight management, but about 10% of those covering plan to drop coverage in 2027 as total spending continues to climb even as per-unit GLP-1 prices have fallen. The Foundayo and Wegovy pill launches drew in patients who had not previously tried GLP-1 therapy, increasing aggregate utilization. Employers that continue covering are layering on management strategies: required participation in a weight-management program, biometric eligibility verification, and restricted prescribing to specific providers. The 2027 employer-coverage cliff is the next financial pressure point for Lilly, Novo, and the pharmacy benefit managers that have built obesity formularies around employer-sponsored plans.
The Endocrine Society's annual meeting ENDO 2026 opened today at McCormick Place West in Chicago and runs through Tuesday June 16, drawing roughly 7,200 attendees and nearly 2,500 abstracts spanning diabetes, obesity, reproductive health, bone health, endocrine-disrupting chemicals, and thyroid cancer. Saturday's plenary 'Unraveling Hormonal Complexity: Genomics, Sex Differences, and Physiology' features I. Sadaf Farooqi (Cambridge) on single-cell genomics and Holly A. Ingraham (UCSF) on hormones and brain-body physiology. Peptide-anchored programs concentrated in the hypoparathyroidism (Ascendis, MBX, Entera), acromegaly (Crinetics), and oral GLP-1 (Entera EB618 preclinical) tracks; oncology-peptide tracks include OAR-targeted radioligand abstracts and copper-peptide bone-resorption work.
Parabilis Medicines (Nasdaq: PBLS) opened June 10 at $33.35 and closed at $31.60 on its Nasdaq debut, a 58% first-day gain after pricing an upsized $670 million IPO at $20 per share — above the previously announced $17-19 range and well past the $476 million initial target Parabilis set on June 4. The 33.5 million-share offering breaks the venture-backed biotech IPO record. Proceeds extend runway for the lead asset zolucatetide, a cell-penetrating helical peptide targeting Wnt/β-catenin in cancer, with a Phase 3 in desmoid tumors expected in the first half of 2027.
Novo Nordisk launched the Wegovy pill in the United Arab Emirates on June 3, the first country outside the US to make the oral semaglutide tablet available since the January 5 US launch. The UAE rollout used a distribution structure that piggybacks on existing diabetes-channel infrastructure rather than a parallel direct-to-consumer build, and arrived ahead of the UK MHRA approval today. Novo had previously guided to second-half 2026 for international rollouts.
Moes Group, a California-based private and white-label skincare manufacturer, announced June 6 that it is producing blue copper peptide (GHK-Cu / copper tripeptide-1) skincare and haircare formulations for brand partners, with cosmetic-grade GHK-Cu in stock and production already running. The launch arrives as the topical GHK-Cu market broadens after FDA materials in May indicated that non-injectable GHK-Cu would return to Category 1 under the 503A process; the injectable form remains pending the second PCAC review scheduled before February 2027.
A June 7 Novo Nordisk announcement, timed to ADA 2026, said the Wegovy pill (oral semaglutide 25 mg) had surpassed 3 million US prescriptions since its January 5 launch, with one prescription filled roughly every five seconds. The first million took 12 weeks (to March 23); the next 2 million came in 10 weeks. More than 80% of new Wegovy pill scripts go to patients new to GLP-1 therapy, suggesting market expansion rather than brand switching, and the first international launches outside the US are set for the second half of 2026.
Hims & Hers' proxy report ahead of the June 11 virtual annual meeting shows 2025 revenue at $2.35 billion (up 59%), 2.5 million-plus subscribers, $318 million adjusted EBITDA, and $300 million operating cash flow. The company's GLP-1 pivot now leans on the Lilly tie-up (Zepbound vials and KwikPens, plus Foundayo via LillyDirect; Bank of America lifted its price target to $32) and the renewed Novo Nordisk partnership for branded Wegovy. The compounded-semaglutide business is winding down ahead of the FDA 503B exclusion that becomes effective after the June 29 comment window closes.
Pfizer's ADA Phase 2b readout for berobenatide (15.9% weight loss at 32 weeks, no plateau, monthly dosing via a 0.5 mL low-volume injection) validates the $4.9 billion Metsera acquisition that closed earlier this year. The company now plans more than 20 obesity-related trials in 2026, including 10 Phase 3 studies. Monthly dosing positions berobenatide against once-weekly incumbents on the adherence axis, the same logic behind Amgen's MariTide and Ascletis's ASC30.